• About
  • Masthead
  • License Content
  • Advertise
  • Submit Press Release
  • RSS/Email List
  • Write for us
  • Contact us
2 Minute Medicine
No Result
View All Result

No products in the cart.

SUBSCRIBE
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
2 Minute Medicine
  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • AccountLog-in/out
    • Subscribe
    • Sign-in
    • My account
SUBSCRIBE
2 Minute Medicine
Subscribe
Home All Specialties Infectious Disease

Lincocin associated with better outcomes than Azitro in treatment of COVID-19 associated pneumonia

byKathleen LauandAlex Chan
July 20, 2020
in Infectious Disease, Pulmonology
Reading Time: 2 mins read
0
Share on FacebookShare on Twitter

RELATED REPORTS

SAR-CoV-2 infection during pregnancy may lead to adverse neurodevelopmental outcomes in male offspring

Molnupiravir and nirmatrelvir-ritonavir reduce COVID-19 mortality in hospitalized patients

Past infection with pre-omicron variants of COVID-19 protects against re-infection

1. Lincocin® appeared to outperform Azitro® in the treatment of pneumonia associated with Covid-19.

Evidence Rating Level: 2 (Good)

Although as much as 80% of patients show only minor symptoms from contracting Covid-19, complications such as pneumonia can arise from Covid-19, especially in elderly patients and individuals with chronic conditions. There is currently no standard treatment for Covid-19 associated pneumonia, but Lincocin®  and Azitro® are both potential candidates. Lincocin®, which has been clinically superseded by its derivative clindamycin and is no longer widely available, covers organisms such as staphylococci, streptococci, and pneumococci, while Azitro® continues to be used in a variety of infections, from respiratory tract infections to STIs.  Both antibiotics bind to the same 50S ribosomal subunit to inhibit bacterial protein synthesis. In this randomized clinical trial, 24 patients with Covid-19 associated pneumonia were randomly assigned to be administered either Lincocin® or Azitro®, with 12 patients in each treatment group. The test period lasted 5 days: 500 mg of Lincocin® was administered twice daily, whereas 500 mg of Azitro® was administered on Day 1 and 250 mg for each of Days 2 through 5. Bronchoalevolar-lavage fluid from each patient was analyzed for Covid-19 RNA before and after the test period, using RT-PCR. In the Lincocin® group, 10 of the 12 participants tested negative, whereas in the Azitro® group, 4 of the 12 participants tested negative (p = 0.012). Although Lincocin® is used to treat secondary bacterial infections, the authors believe that its efficacy as an antiviral pneumonia treatment stems from the use of lincomycin hydrochloride and benzyl alcohol as a preservative. Implications of this study are specific to Covid-19 associated pneumonia, with Lincocin® showing higher efficacy than Azitro® in reducing viral load in the lungs. Meanwhile, previous studies have demonstrated reduced viral load from giving combination hydroxychloroquine and azithromycin therapy. Limitations of this study include its small sample size and lack of reporting on adverse effects; further research should test the effiacy of these two single agents in combination with other antiviral agents in treating Covid-19 associated pneumonia.

Click to read this study in the Journal of Population Therapeutics & Clinical Pharmacology

©2020 2 Minute Medicine, Inc. All rights reserved. No works may be reproduced without expressed written consent from 2 Minute Medicine, Inc. Inquire about licensing here. No article should be construed as medical advice and is not intended as such by the authors or by 2 Minute Medicine, Inc.

Tags: pulmonologySARS-CoV-2
Previous Post

Hydroxychloroquine ineffective as post-exposure prophylaxis for Covid-19

Next Post

Identification of a genetic susceptibility locus in patients with severe Covid-19

RelatedReports

Paternal factors associated with short interpregnancy interval
Infectious Disease

SAR-CoV-2 infection during pregnancy may lead to adverse neurodevelopmental outcomes in male offspring

March 29, 2023
SARS-CoV-2 detected on various surroundings of asymptomatic COVID-19 positive infant
Infectious Disease

Molnupiravir and nirmatrelvir-ritonavir reduce COVID-19 mortality in hospitalized patients

March 29, 2023
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

Past infection with pre-omicron variants of COVID-19 protects against re-infection

March 28, 2023
Decreased expression of nasal ACE2 may be correlated with lower prevalence of COVID-19 in children
Chronic Disease

Symptom and viral relapse more common in COVID-19 patients without antiviral treatment

March 21, 2023
Next Post
Critically ill COVID-19 patients may benefit from convalescent plasma therapy

Identification of a genetic susceptibility locus in patients with severe Covid-19

#VisualAbstract: An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic

#VisualAbstract: An outbreak of severe Kawasaki-like disease at the Italian epicentre of the SARS-CoV-2 epidemic

Non-invasive prenatal testing linked to decreased diagnostic testing

RNA-Binding Protein RBFOX1 May Be Locus for Alzheimer’s Disease Pathogenesis

License Our Award-Winning Physician-Written Medical News and Visual Abstracts

2 Minute Medicine is the leading authoritative medical news licensing service, and the only with reports written by practicing doctors.

LICENSE CONTENT

2MM+ Premium Access

No ads & unlimited access to all current reports, over 9000 searchable archived reports, visual abstracts, Weekly Rewinds, and the online edition of The Classics Series™ textbook.

Subscription Options
2 Minute Medicine

2 Minute Medicine® is an award winning, physician-run, expert medical media company. Our content is curated, written and edited by practicing health professionals who have clinical and scientific expertise in their field of reporting. Our editorial management team is comprised of highly-trained MD physicians. Join numerous brands, companies, and hospitals who trust our licensed content.

Recent Reports

  • Addition of fludrocortisone to hydrocortisone is beneficial in management of septic shock
  • Surveillance testing of staff at nursing facilities reduces resident COVID-19 mortality
  • Childhood maltreatment may cause mental health problems
License Content
Terms of Use | Disclaimer
Cookie Policy
Privacy Statement (EU)
Disclaimer

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

  • Specialties
    • Cardiology
    • Chronic Disease
    • Dermatology
    • Emergency
    • Endocrinology
    • Gastroenterology
    • Imaging and Intervention
    • Infectious Disease
    • Nephrology
    • Neurology
    • Obstetrics
    • Oncology
    • Ophthalmology
    • Pediatrics
    • Preclinical
    • Psychiatry
    • Public Health
    • Pulmonology
    • Rheumatology
    • Surgery
  • The Scan
  • Wellness
  • Classics™
    • 2MM+ Online Access
    • Paperback and Ebook
  • Rewinds
  • Visual
  • Partners
    • License Content
    • Submit Press Release
    • Advertise with Us
  • Account
    • Subscribe
    • Sign-in
    • My account

© 2021 2 Minute Medicine, Inc. - Physician-written medical news.

Want more physician-written
medical news?

Join over 10 million yearly readers and numerous companies. For healthcare professionals
and the public.

Subscribe for free today!

Subscription options